MapLight shares sink on mixed ph. 2 schizophrenia readout

Velocity

How fast coverage is spreading — measured hourly from article rate × source diversity. How this works →

Coverage (6)

• Maplight aims to differentiate muscarinic agonist from competitors BioWorld News · 9h ago
• MapLight dives despite positive data for schizophrenia drug BioPharma Dive · 9h ago
• MapLight Therapeutics (MPLT) Rally Puts Its CNS Story And Valuation In Focus simplywall.st · 9h ago
• Biotech And AI Stocks Got Hit On Mixed News Finimize · 9h ago
• Phase 2 Topline Results From ZEPHYR Trial: ML-007C-MA for the Treatment of Schizophrenia Psychiatric Times · 9h ago
• MapLight shares sink on mixed ph. 2 schizophrenia readout Fierce Biotech · 9h ago

Related trends